Respiratory infections: how does a virus spread inside a body and through the population?
Four Joint Research Centre (JRC) designed epidemiological and viral kinetics models will enhance understanding of respiratory disease dynamics, contributing to a better preparedness of future infectious disease outbreaks.
Nirsevimab Effectiveness Against Severe RSV Infection in the Primary Care Setting
This study assesses the effectiveness of nirsevimab, a monoclonal antibody, in preventing medically attended respiratory syncytial virus-lower respiratory tract infections (RSV-LRTI) in a large primary care network in Spain.
What are the risks of RSV infections for older individuals?
ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.
Is RSV a serious illness?
ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.
How can you tell the difference between RSV and other respiratory diseases, like COVID-19 or influenza?
ESWI addresses common questions and misconceptions amongst the general public regarding influenza, COVID-19 and RSV. These responses, elaborated by ESWI Board Members and coalition partners, aim to increase public awareness and prevent misinformation.
Respiratory Syncytial Virus Infection in Older Adults: An Update
Respiratory syncytial virus (RSV) infection represents one of the most common infections during childhood, with significant morbidity and mortality in newborns and in the early years of life.
How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?
Respiratory syncytial virus (RSV) and influenza infections cause significant annual morbidity and mortality worldwide in at-risk populations.
Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection
Respiratory syncytial virus (RSV) infection can cause severe respiratory illness in older adults.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol
Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.
|
ESWI Respiratory Virus Summit 2024
ESWI Respiratory Virus Summit 2024 Summary Report
Building on the 2023 session held at the ESWI conference in Valencia "RSV Looking towards the future", this one-day summit concentrated on the healthcare and economic impact of RSV disease, along with the potential solutions expected in the near future.
|
9th Influenza Conference 2023
Scientific highlights of the 9th ESWI Influenza Conference
With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.
ECDC on Air podcast. Why Monitoring Respiratory Viruses Matters?
In this episode, ECDC expert on respiratory viruses, Nick Bundle, gives the lowdown on the European Respiratory Virus Surveillance Summary (ERVISS), a new surveillance tool which presents weekly data on influenza, SARS-CoV-2 and RSV.
